ArticleDrugs in R&D2017

Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.

Eiji Kutoh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.